Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer

PURPOSE: This single-arm, open label Phase II study evaluated the safety and efficacy of taselisib (GDC-0032) plus fulvestrant in postmenopausal women with locally advanced or metastatic HER2-negative, hormone receptor (HR)-positive breast cancer. EXPERIMENTAL DESIGN: Patients received 6 mg oral tas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Dickler, Maura N., Saura, Cristina, Richards, Donald A., Krop, Ian E., Cervantes, Andrés, Bedard, Philippe L., Patel, Manish R., Pusztai, Lajos, Oliveira, Mafalda, Cardenas, Alison K., Cui, Na, Wilson, Timothy R., Stout, Thomas J., Wei, Michael C., Hsu, Jerry Y., Baselga, José
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6139036/
https://ncbi.nlm.nih.gov/pubmed/29793946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0613
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge